(Q42848515)

8 November 2017

Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer (English)

1 reference

8 November 2017

1 reference

1 reference

2

1 reference

8 November 2017

Alexandr V Bazhin

1

1 reference

8 November 2017

Viktor Umansky

series ordinal

3

1 reference

8 November 2017

Jens Werner

series ordinal

4

1 reference

8 November 2017

Svetlana Karakhanova

series ordinal

5

1 reference

8 November 2017

23 July 2013

1 reference

8 November 2017

1 reference

8 November 2017

2

1 reference

8 November 2017

9

1 reference

8 November 2017

e25736

1 reference

Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma

8 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3850017

Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3850017

Immunomodulatory effects of cyclophosphamide and implementations for vaccine design

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3850017

Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3850017

Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3850017

Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3850017

Early detection of pancreatic carcinoma

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3850017

Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3850017

Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States).

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3850017

Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24327934

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4161/ONCI.25736

1 reference

8 November 2017

1 reference

8 November 2017

PubMed publication ID

24327934

1 reference